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Objectives: Pulmonary embolism (PE) is one of the major complications after percutaneous balloon angioplasty (PTBA)
for Budd-Chiari’s syndrome (BCS). The purpose of this study was to investigate the role of warfarin pre-treatment in the
prevention of PE after PTBA in patients with large inferior vena cava (IVC) thrombus.
Patients and Methods: From October 2002 to December 2009, 16 patients with symptomatic membranous or segmental
IVC occlusion and large thrombus were treated with warfarin before PTBA. Eleven patients were men and 5 were women.
The median age was 36 years, ranging from 21 to 52 years. The median duration of warfarin treatment before PTBA was
7 months, ranging from 3 to 12 months. Fourteen patients had membranous IVC occlusion and 2 had segmental
occlusion. All 16 patients had significant thrombi underneath the obstructive lesions. PE diagnosis was based on clinical
presentation and pulmonary computerized tomographic angiogram, if indicated.
Results: In 14 of 16 patients, IVC thrombus was completely or near-completely resolved based on follow-up cavogram
and PTBA was performed. In the other 2 patients, residual thrombus was demonstrated by cavogram at 12 months.
PTBA and stent placement were carried out. IVC patency in the 16 patients was confirmed by completion cavogram. No
major bleeding complication during warfarin pre-treatment aimed to keep international normalized ratio (INR) 2 to 3.
There was no clinically significant PE or death in this group during follow-up, ranging from 6 to 40 months (median 21
months).
Conclusion: Spontaneous fibrinolysis of IVC thrombus occurs within 1 year in the majority of the patients treated with
warfarin. Pre-treatment with warfarin prevents PE after PTBA in the patients with BCS with IVC membranous or
segmental occlusion and large thrombus. (J Vasc Surg 2010;52:1242-5.)Budd-Chiari syndrome (BCS) is characterized by he-
patic venous outflow obstruction from the level of hepatic
veins up to the junction of the inferior vena cava (IVC) with
the right atrium.1,2 The management modalities published
include anticoagulation and underlying disease treatments,
percutaneous transhepatic balloon angioplasty with or
without stenting, transjugular intrahepatic portosystemic
shunt, surgical shunts, and liver transplantation.3-6 Less
invasive percutaneous transluminal balloon angioplasty
(PTBA) with or without stenting has been recently recom-
mended as a first-line treatment for obstructed IVC at or
above hepatic level in primary BCS.7-9 However, pulmo-
nary embolism (PE) has been a major concern during or
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1242after PTBA, especially in the patients with large IVC
thrombus. The death rate secondary to PE has been re-
ported as high as 11%.10-12
The purpose of this study was to evaluate the effective-
ness of pre-treatment with warfarin in the prevention of PE
after PTBA in patients with IVC occlusion and large throm-
bus. From 2002 to 2009, 16 patients in our group were
treated by PTBA after warfarin anticoagulation. There was
no clinically significant PE or death.
MATERIALS AND METHODS
From October 2002 to December 2009, 362 patients
with BCS were treated at the People’s Hospital of Henan
Province in China. Nineteen of 362 patients (5%) were
found to have large IVC thrombus. Sixteen were treated
with warfarin before PTBA. Twelve of them had membra-
nous IVC obstruction and 4 had segmental occlusion. The
median age was 36 years, ranging from 21 to 52 years. The
median duration of warfarin treatment before PTBA was 7
months, ranging from 3 to 12 months. All 16 patients
presented with chronic symptoms over 3 months (Table).
Lower extremity edema, varicose veins, and venous ulcers
were managed with leg elevation, compression stockings,
and local wound care. Significant ascites was treated with
diuretics. There was no clinical deterioration during anti-
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improved after PTBA (Table).
Three of 19 patients with IVC thrombus presented
with massive gastrointestinal bleeding or acute jaundice.
They were excluded from this study because emergent or
urgent PTBA with stenting was required. One of 3 patients
(33%) developed PE during the procedure, but there were
no deaths.
IVC thrombus was diagnosed by Duplex ultrasound
scan. Significant IVC thrombus was defined as the clots
causing diameter reduction greater than 30%. Workup for
hypercoagulable states was negative in the 16 patients.
Warfarin was administrated orally to keep international
normalized ratio (INR) between 2 and 3. Clinical exami-
nations and sonography, or computed tomography scan, or
cavogram were repeated every 3 months to assess for reso-
lution of IVC thrombosis. PTBA was performed when
the follow-up imaging study showed complete or near-
complete resolution of the thrombus. In the patients with
residual IVC thrombus, warfarin was given up to 12 months
before PTBA. Warfarin was withheld 5 days before the
procedure. No bridging anticoagulation was given. During
the procedure, the patients received full dose heparin (100
units/kg). Stent placement after PTBA was indicated if
significant residual thrombus was demonstrated.
PTBA of the IVC occlusive lesions, using a 30-mm
semi-compliant Balt Cristal balloon (Balt Extrusion,Mont-
morency, France) or compliant 32-mm Coda Balloon
(Cook Medical, Bloomington, Ind), was carried out in 14
patients who had complete or near-complete resolution of
the thrombus. In the other 2 patients with residual throm-
bosis, a Z-stent (Micro-Tech, Nanjing, Jiangsu, China) was
placed to compress the thrombus onto the wall of the IVC
to prevent clot dislodgement and PE. The right common
femoral vein was used as the first choice of access. The
occlusive lesions were traversed using Kumpe catheter and
Glidewire. After IVC occlusion was crossed, the Glidewire
was switched to a superstiff wire. PTBA was performed
under fluoroscopy. In the patients with residual IVC
thrombus, a Z-stent was inserted to hold the thrombus in
place and followed by IVC dilation with a 30-mm balloon
catheter. Pre-dilatation with a 4-mm balloon may be
needed for Z-stent insertion. Post-PTBA IVC patency was






Stomach bloating 15 (94%) 1 (6%)
LE edema 16 (100%) 1 (6%)
Varicose vein 13 (81%) 9 (56%)a
LE venous ulcer 2 (13%) 0
Hepatomegaly 11 (69%) 1 (6%)
Ascites 6 (38%) 0
LE, Lower extremity; PTBA, percutaneous transluminal balloon angioplasty.
aThe 9 patients with residual varicose veins had improvement after PTBA.confirmed by completion cavogram in all patients.Warfarin was discontinued and aspirin was given to all
the patients after successful PTBA/stenting. Follow-up was
scheduled every 3 months up to 12 months, and then
changed to every 6 months if the patient was stable with
patent IVC. Clinical symptoms, liver function tests, and
ultrasound scans of the IVC and hepatic veins were period-
ically performed.
RESULTS
Warfarin aimed to keep the INR between 2 to 3 was
well-tolerated in all 16 patients, without major bleeding
complications. The patients remained stable and did not
need to abandon warfarin treatment for emergent interven-
tion. The symptoms disappeared or significantly improved
after PTBA (Table). The durations of warfarin treatment
were based on the fibrinolysis and resolution of IVC throm-
bus. It was stopped within 3 to 6 months in 10 patients, 6
to 9 months in 4 patients, and 9 to 12 months in 2 patients.
Fourteen of 16 patients (88%) with complete or near-
complete resolution of IVC thrombosis underwent PTBA
(Figs 1 and 2), the other 2 patients with residual IVC
thrombus had PTBA and Z-stent placement. Completion
cavogram confirmed the IVC was widely patent in all 16
patients without residual thrombosis. No bleeding compli-
cations occurred in this group.
Median follow-up was 21 months (range, 6-40
months) after PTBA with or without stent placement.
Patent IVC was demonstrated by Duplex ultrasound scan
or computed tomography scan, and there was no evidence
of recurrent stenosis in all 16 patients. There was no PE,
recurrent symptoms, or death in our group during the
follow-up periods up to 40 months.
DISCUSSION
BCS is a rare condition caused by obstruction of IVC
and/or hepatic veins. A wide variety of etiologies have been
documented. In Asian and African population, membra-
nous occlusion of the IVC and/or hepatic veins is themajor
cause of hepatic venous outflow obstruction,13 whereas
thrombosis is the most frequent etiology in Western coun-
tries.3
Due to the rarity of BCS, no controlled prospective
study has been performed. The treatment modalities pub-
lished include anticoagulation and underlying disease man-
agement, percutaneous transhepatic balloon angioplasty
with or without stenting, transjugular intrahepatic porto-
systemic shunt, surgical shunts, and liver transplanta-
tion.3-6
Plessier et al14 reported that conservative management
alone was successful in only less than 20% of the patients
with BCS. The use of a surgical portosystemic shunt in the
treatment of BCS is debated because the perioperative
mortality has been documented up to 50%.15-17 Therefore,
open shunting procedures have been almost abandoned in
Europe.18 Liver transplantation is recommended to be
reserved for patients with presentations of culminant he-
patic failure and endstage chronic cirrhosis.5
tentin
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increasing role in the treatment of BCS in recent years. A
retrospective review demonstrated that the mortality rates
were 14% in the patients undergoing percutaneous inter-
vention vs 44% in the open shunting group.19However, PE
has been a major concern during the PTBA. The death rate
secondary to PE after PTBA has been reported as high
as 11%.10-12
Although local thrombolysis has been reported, favor-
able outcomes may only be achieved in the patients with
acute symptoms due to fresh thrombosis in IVC or hepatic
veins.20 In our group, all the patients presented with
chronic symptoms over a few months. They do not need
emergent or urgent intervention, and pre-treatment with
Fig 1. A, Diagnostic cavogram revealed inferior ven
Follow-up cavogram after 3-month warfarin pre-treatmen
C, Percutaneous transluminal balloon angioplasty (PTBA
IVC was widely patent following PTBA.
Fig 2. A, Diagnostic cavogram revealed inferior vena c
Follow-up cavogram after 6-month pre-treatment with w
C, Percutaneous transluminal balloon angioplasty was p
cavogram showed the IVC was widely patent and IVC swarfarin was allowed. It has been reported that the meanrecanalization rate in deep venous thrombosis of lower
extremity was approximately 72% to 93% within 12 months
in the patients treated with anticoagulants.21,22 The mech-
anism of recanalization in deep venous thrombosis was
well-described by Sevitt.23 To our knowledge, no data have
been published to document the spontaneous fibrinolysis
process in IVC thrombosis. Our study demonstrated that
fibrinolysis dissolved the IVC thrombi in 88% of our pa-
tients (14 of 16). As we know, anticoagulation itself does
not have fibrinolytic activity. However, it can prevent fur-
ther clot formation while allowing the body’s natural fi-
brinolytic system to dissolve the existing clot spontane-
ously.
IVC stenting was used to compress thrombus onto the
a (IVC) occlusion with large thrombus (arrows). B,
onstrated near-complete resolution of IVC thrombosis.
s performed for this membranous obstructive lesion. D,
IVC) occlusion with a large IVC thrombus (arrow). B,
in demonstrated the thrombus was completely resolved.
ed for this segmental occlusive lesion. D, Completion




erformcaval wall to prevent PE in the patients with significant
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complication is not uncommon.8,25,26 In our group, stent
placement and its potential migration complication was
avoided in 88% of the patients pre-treated with warfarin.
There was no clinical significant PE or death, and IVC
remained patent in all the patients during the follow-up of
6 to 40 months.
In conclusion, our preliminary results suggest that pre-
treatment with warfarin may effectively prevent PE after
PTBA in the patients with BCS with large thrombus. It is
safe and cost-effective in the patients who do not require
emergent or urgent intervention. Warfarin pre-treatment
also minimizes the requirement of IVC stenting and its
potential migration complications. Further investigation is
needed to evaluate the long-term IVC patency.
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